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Summary: Calcitonin gene-related peptide, originally found in rat medullary thyroid carcinoma cells, was
measured by radioimmunpassay in plasma samples with added aprotinin from 17 normal volunteers and 21
patients with medullary thyroid carcinoma. The concentrations were below 75 pmol/1 in all 17 normal subjects
with a mean of 33 ±19 pmol/1 plasma. In the patients, the plasma calcitonin gene-related peptide concentra-
tions ranged from below 5 pmol/1 to 236 pmol/1, although the mean (36 ± 48 pmol/1) was not significantly
different from the mean normal level. Increase in the plasma calcitonin gene-related peptide level was observed
in 2 of 5 patients in response to infusion of 4.3 mg/kg of calcium for 10 minutes and in 3 of S patients in
response to infusion öf 4 g/kg of tetragastrin for 5 minutes. These observations suggest that measurement
of calcitonin gene-related peptide level may be helpful in determination of diseases in which the level of
calcitonin is of less diagnostic value.
Introduction calcitonin is mainly synthesized in the thyroid, and
__ r . , , . t . - „ . . - - 1 . . calcitonin gene-related peptide mainly in the centralWith the Isolation of a cell stram with low calcitonin .
1 . . . , . . x 14. nervous System (3,4).synthesizmg capacity by repetitive metagenetic cultüre
pf rat medullary thyroid carcinoma cells, it became Unlike many other known peptides, calcitonin gene-
possible to stüdy the mode of expressiön of the cal- related peptide was synthesized artificially by a pro-
citonin gene; this cell strain was shown to synthesize cedure established on the basis of molecular analysis
calcitonin gene-related peptide, which differs from of the calcitonin gene, and it was then detected in
calcitonin (1). It is now generally accepted that twö vivo by an immunohistological method. Calcitonin
kinds of peptides are coded by the calcitonin gene, gene-related peptide reportedly exerts various phys-
and that mRNA transcribed from the calcitonin gene iological actions, such äs suppression of appetite (5),
undergoes two alternative types of splicing to become inhibitipn of secretion of gastric acid or gastric juice
calcitonin mRNA (which encodes calcitonin) or cal- (6, 7), vasodilatation (8), Inhibition of gallbladder
citonin gene-related peptide mRNA (which encodes contractility (9), and Stimulation of secretions of renin
calcitonin gene-related peptide) (2, 3). This splicing (10) and atrial natriuretic peptide (11). Immunohis-
mechanism has been reported to be organ-^specific: tological studies have shown that calcitonin gene-
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related peptide is widely distributed in the central
nervous System (4, 12, 13) and in peripheral ganglia
(14), suggesting that it may be an neurotransmitter.
However, the physiological role(s) of this peptide in
humans is unknown. We established a radioimmu-
noassay for the measurement of human calcitonin
gene-related peptide and determined the plasma con-
centrations of this peptide in healthy subjects and
patients with medullary thyroid carcinoma.
Materials and Methods
Materials
Human calcitonin gene-related peptide(l — 37), rat calcitonin
gene-related peptide(l — 37), human calcitonin(l — 32), and hu-
man parathyrin(l — 84) were purchased from the Peptide Insti-
tute (Osaka, Japan). Human 125I-labelled calcitonin gene-related
peptide (74 χ l O15 Bq/mol) was obtained from Amersham
Japan, Ltd. (Tokyo, Japan). Anti-calcitonin gene-related pep-
tide antibody (a gift from Prof. /. Macintyre, Royal Postgrad-
uate Medical School, London, England), was produced by
sensitizing rabbits with rat Tyr°-calcitonin gene related pep-
tide(28-37) coupled with egg albumin (15). Anti-rabbit-glob-
ulin goat serum. and normal rabbit serum were from Eiken
Immunochemical Co. (Tokyo, Japan). All other materials were
from Wako Pure Chemical Co. (Osaka, Japan).
Subjects
The subjects examined were 17 healthy volunteers (mean age
± SD, 31 ± 9 years: r nge, 20-49 years; 4 males and 13
females) and 21 patients with medullary thyroid carcinoma (41
±13 years; 14—63 years; 4 males and 17 females). The diag-
nosis of medullary thyroid carcinoma was established by the
presence of hypercalcitoninaemia either in the basal state or in
response to calcium infusion in the test described below, and
was confirmed surgically in all cases. Blood samples were ob-
tained early in the morning after an overnight fast using syringes
containing 4mmol/l EDTA · 2Na and 0.5 χ l O6 KIU/1 of
aprotinin. Samples were cooled on ice and promptly centri-
fuged, and the plasma was stored at —50 °C until used. Five
of the medullary thyroid carcinoma patients (2 males, 3 females)
received a provocation test with 4.3 mg/kg (iv, 10 minutes) of
calcium (20 g/l calcium Chloride) or 4 μg/kg (iv, 5 minutes) of
tetragastrin, and blood samples were taken before and after the
test.
Radioimmunoassay of calcitonin gene-related pep-
tide
Control plasma was prepared s follows: Normal human pe-
ripheral blood was collected in assay tubes containing 4 mmol/1
EDTA · 2 Na and 0.5 χ ΙΟ6 KIU/1 of aprotinin, and plasma
was separated by centrifugation for 10 minutes at 3000 g. This
normal plasma was mixed with 50 g/kg charcoal (Norite A)
with stirring for l hour and centrifuged at 10000g- for 30
minutes. The resulting supernatant was filtered twice through
a millipore filter (type HA, pore size 0.45 μπι; Millipore Cor-
poration, Massachusetts). The radioactivity of human J25I-la-
belled calcitonin gene-related peptide remaining after this pro-
cedure was less than 1%. For assay of human calcitonin gene-
related peptide the reaction mixture, total volume 500 μΐ, con-
tained 100 μΐ of control plasma (containing Standard human
calcitonin gene-related peptide) or test plasma, about 20000
counts per minute of human 125I-labelled calcitonin gene-related
peptide, anti-calcitonin gene-related peptide serum diluted to a
final concentration of 1:18000, an appropriate amount of
aprotinin to give a final eoncentration of 2 χ ΙΌ6 KIU/1, and
buffer. The buffer employed was 100 mmol/1 sodram phosphate
buffer containing 150 mmol/1 NaCl, 1.2 mmol/1 EDTA, and 15
mmol/1 NaN3 (pH 7.4). After incubation of the mixture of 4 °C
for 48 hours, bound and free human calcitonin gene-related
peptide were separated by the double antibody method, with
the second antibody and normal rabbit serum, with incubation
at 4 °C for 24 hours. Some plasma samples were examined in
an assay System without aprotinin.
Stability of human 125I-labelled calcitonin gene-re-
lated peptide in plasma samples
The stability of human 125I-labelled calcitonin gene-related pep-
tide in plasma was studied s follows. Plasma samples from
normal subjects after overnight fasting were collected in assay
tubes containing 4 mmol/1 EDTA · 2 Na alone. Samples were
incubated s described above and also for 96 hours instead of
48 hours. After incubation, the mixtures were subjected to gel
chromatography on a Bio Gel P-2 column (1.6 χ 50 ein).
Materials were eluted with the assay buffer, and their elution
profiles were compared.
Radioimmunoassay for calcitonin
Plasma calcitonin was determined with a commercial radioim-
munoassay kit (D iichi Radioisotope Laboratories, Ltd., To-
kyo, Japan) by the procedure described previously (16).
Statistical analysis
Statistical analyses were performed by Studenfs t test. Concen-
trations of plasma calcitonin gene-related peptide of less than
the detection limit (5 pmol/1) were taken s 5 pmol/1.
Results
Stability of human 125I-labelled calcitonin
gene-related peptide
Figure l shows the gel-filtration profiles of human
125I-labelled calcitonin gene-related peptide(l — 37) in-
cubated with plasma samples with and without 1000
KlU/tube aprotinin. Most of the radioactivity in sam-
ples incubated for 48 hours without aprotinin was
eluted in the low molecular region, indicating that
much of the tracer was degraded during the incuba-
tion. This degradation progressed during further in-
cubation for up to 96 hours, but was markedly inhib*
itedbylOOOKIU/tube(2 χ l O6 KIU/1) of aprotinine.
Therefore, this concentration of aprotinin was added
in all subsequent assays.
Radioimmunoassay for human calcitonin
gene-related peptide
Figure 2 shows the Standard curve for calcitonin gene-
related peptide. The sensitivity of the assay, defined
s the concentration of human calcitonin gene-related
peptide at a poirxt on the Standard curve 2 Standard
deviations from the maximum binding (BQ), was
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Fig. l,
Distribution coefficient
Degradation of human 125I-labelled calcitonin gene-re-
lated peptide in normal plasma. Plasma was incubated
with and without 1000 KlU/tube of aprotinin at 4 °C
for 48 hours or 96 hours. It was then analysed by gel-
chromatography on a Bio Bei P-2 1.6 χ 50 cm column
developed with 100 mmol/1 sodium phosphate buffer,
pH 7.4, containing 150 mmol/1 NaCl, 1.2 EDTA and
15 mmol/1 NaN3. Symbols: ·—e, control; o—o, with
aprotinin for 48 hours; Δ — Δ , with aprotinin for 96
hours; o—o, without aprotinin for 48 hours; A — A ,
without aprotinin for 96 hours.
Plasma calcitonin gene-related peptide levels
in normal subjects and patients with medul-
lary thyroid carcinoma
As shown in figure 3, the basal plasma concentrations
of calcitonin gene-related peptide in normal subjects
ranged from below the detection limit (< 5pmol/l)
to 75 pmol/1, with a mean of 33 ± 19 pmol/1. The
basal calcitonin gene-related peptide concentrations
in medullary thyroid carcinoma patients ranged from
below the detection limit to 236 pmol/1, although the
mean level in this group (35 ± 48 pmol/1) did not
differ significantly from that in the normal group.
Figure 4 shows the relation between the plasma cal-
citonin and calcitonin gene-related peptide levels in
the 21 patients with medullary thyroid carcinoma.
There was a significant correlation (r = 0.48,
p < 0.05) between the two parameters after their log-
arithmic transformation.
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Fig. 2. Standard curve of human calcitonin gene-related pep-
tide with (·)" and without (o) 1000 KlU/tube of apro-
tinin, and ccpss-reactivities of rat calcitonin gerierrelated
peptide (A), human-calcitonin(l — 32) (Δ) and human
parathyrin(l—84) (D) with antiserum.
5 pmol/1. The curve was not s tisfactory in the absence
of aprotinin. The intra* and iriterassay coefficients of
Variation were 6.0% and 8.0%, respectively, and the
recovery was 104.9 ± 16.7%. When plasma samples
containing three different concentfations of human
calcitonin gene-related peptide were diluted sequen-
tially, the res ltant dilution curve of each showed
good linearity. The cr ss-reactivity of anti-rat Tyr°-
calcitonin gene-related peptide(28—37) rabbit-serum
with human calcitonin gene-related peptide(l —37)
was 56% of its reactivity with rat calcitonin gene^
related peptide(l—37). However, no cross-reactivity
with either human calcitonin(l — 32) or human para-
thyrin(l —84) was detected (fig. 2).
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Fig. 3- Plasma calcitonin gene-related peptide levels in 17 nor-
mal subjects and 21 patients with medullary thyroid
carcinoma.
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Fig. 4. Correlation of plasma concentations of calcitonin and
calcitonin gene-related peptide in 21 patients with med-
ullary thyroid carcinoma. Linear regression of loga-
rithmically transformed data on individual plasma con-
centrations of calcitonin gene-related peptide and cal-
citonin showed a significant correlation (r = 0.48,
p < 0.05).
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Table l shows the responses of plasma calcitonin and
calcitonin gene-related peptide to infusion of calcium
and tetragastrin in five patients with medullary thy-
roid carcinoma. The plasma calcitonin levels in all
five patients increased significantly in response to
these provocation tests, but increases in the plasma
calcitonin gene-related peptide levels were observed
in only 2 patients in the former test and 3 patients in
the latter test.
Tab. 1. Plasma concentrations of human calcitonin and calci-
tonin gene-related peptide in response to intravenous
administration of 4.3 mg/kg calcium and of 4 g/kg of
tetragastrin in 5 patients with medullary thyroid car-
cinoma.
Patient i ·* · / i n\ Plasma calcitonin gene-Plasma calcitonin (pmol/1)
 related peptide
Basal 10 min Basal 10 min
Calcium infusion test
l 539
2
3
4
5
1878
2723
208
605
827
4282
32846
388
16322
64
51
45
23
24
78
30
60
<5
18
Gastrin infusion test
1
2
3
4
5
556
2989
14672
216
3183
735
13416
32562
315
7776
54
34
41
12
26
52
66
52
23
16
Discussion
The anti-rat-Tyr° calcitonin gene-related peptide(28 —
37) antibody used in this study was reported to cross-
react with rat calcitonin gene-related peptide and hu-
man calcitonin gene-related peptide, but not with
many other peptide hormones such äs human para-
thyrin, adrenocorticotropin, substance P, somatosta-
tin and oxytocin (13). In our experiment, the cross-
reactivity of human calcitonin gene-related peptide
with this antibody was 56% of that of rat calcitonin
gene-related peptide. Our assay System seems to be
suitable for clinical use because a satisfactory Stand-
ard curve was obtained and good reproducibility of
recovery was observed in dilution experiments.
Furthermore, the present study demonstrated that
human 125I-labelled calcitonin gene-related peptide
was degraded appreciably in the plasma, and that this
degradation was inhibited by aprotinin, an inhibitor
of proteolytic enzymes. Kraenzlin et al. reported that
calcitonin gene-related peptide was rapidly degraded
in vivo, and that its half life in the circulatiön was
less than 30 minutes (17). These results süggest that
plasma should be promptly separated and stored in
an assay tube containing aprotinin, and that aprotinin
should also be added before assays to prevent possible
degradation of calcitonin gene-related peptide during
incubation.
Recently, a method for measuring human calcitonin
gene-related peptide by radioimmunoassay was re-
ported by Zaidi et al. (18). In their assay System, the
detection limit was 5 pmol/1, and the crpss-reactivity
of human calcitonin gene-related peptide with the
antibody was 60% of that of rat calcitonin gene-
related peptide. They also used aprotinin for pre-
venting degradation of the peptide. Thus our assay
system was comparable with theirs.
By our assay, the mean circulating concentration of
calcitonin gene-related peptide in normal subjeets was
33 ± 19 pmol/1, which was similar to the value re-
ported by Girgis et al. (19).
Calcitonin gene-related peptide was first discovered
in a inolecular biological study of rat medullary thy-
roid carcinoma, and its level is thought to be elevated
in patients with medullary thyroid carcinoma: in fact
there are some reports of high levels of calcitonin
gene-related peptide in these patients. An early report
revealed rather high levels of circulating calcitonin
gene-related peptide in patients with medullary thy-
roid carcinoma, but did not give details of the assay
Systems, including whether aprotinin was used to pre-
vent degradation of the tracer in the assay system
(15). Mason et al. measured circulating calcitonin
gene-related peptide after extraction of plasma by acid
ethanol, and detected high levels of calcitonin gene-
related peptide of 14-4866 pmol/1 in 19 of 21 patients
with medullary thyroid carcinoma, but plasma con-
centrations of below the detection limit (10 pmol/1)
in the other two patients (20). They also observed
increases in the circulating level of calcitonin gene-
related peptide in response to calcium and/or gastrin
infusion in 6 patients (20). Schifter et äl. also detected
high basal levels of calcitonin gene-related peptide in
26 of 35 patients with medullary thyroid carcinoma,
using a radioimmunoassay system with aprotiniü.
They observed significantly higher circulating levels
of calcitonin than those of calcitonin gene-related
peptide in these patients, but they also observed that
the ratio of the two peptides varied from patient to
patient and that only a small number of eells in
tumoürs were stained by änti-cälcitonin geöe-related
peptide antibody (21). However, in our study, äl-
though the basal level of calcitonin gene-related pep-
tide was high in oüe medullary thyröid carcinoma
patient, the mean level in medullary thyroid carci-
noma patients was not significantly different ffom
that of normal controls. Moreover, changes in calci-
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tonin gene-related peptide levels after provocation
with calcium or gastrin, which is known to stimulate
calcitonin in man, differed in different individuals and
were only modest in our study, although Mason et al.
observed rather high responses of circulating calci-
tonin gene-related peptide in most of their patients
with medullary thyroid carcinoma in these provoca-
tion tests.
The reason for the differences in the mean basal levels
of calcitonin gene-related peptide and in its responses
in provocation tests in our study and the studies of
Mason et al. and Schifter et al. is unknown. A possible
explanation is that the patients examined were in
different stages of disease. Our patients may have
been in a rather earlier stage of disease, äs their
circulating calcitonin levels ranges from 10 pmol/1 to
3.3 nmol/1 whereas those of most of the patients of
Mason et al. and Schifter et al. were more than our
highest level, and ranged up to more than 100 nmol/1.
The medullary thyroid carcinoma patients reported
by Mason et al. and Schifter et al. included those with
the much higher levels of circulating calcitonin than
those in our study. But a few of their patients had
calcitonin levels that were about the same äs those in
our study, and these patients had similar plasma cal-
citonin gene-related peptide levels to those of our
patients. Schifter et al. reported that calcitonin gene-
related peptide values increased rapidly in the terminal
phase of this disease, and Mason et al. also stated
that in their study the two patients with the highest
plasma calcitonin gene-related peptide levels had par-
ticularly aggressive tumours.
It is interesting that the plasma calcitonin and calci-
tonin gene-related peptide levels in our medullary
thyroid carcinoma patients in the early stage of the
disease showed a significant positive correlation, since
similar correlations were observed in the medullary
thyroid patients studied by Mason et al. and Schifter
etal.
More extensive studies are necessary on the secretion
of calcitonin gene-related peptide and its behaviour
in the circulation in both normal subjects and patients
with medullary thyroid carcinoma.
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MD-Kova-System zur standardisierten
lipeitung und Auswertung des Urin-
ents ist inzwischen als Standard bei der
lentuntersuchung in Klinik und Praxis zu
iibhnen. Weltweit wurden 1988. über
lilionen Urinanalysen mit dem MD-Kova-
6 m durchgeführt.
n setzt das standardisierte Sediment
\/laßstäbe in der Hygiene bei Urinunter-
ngen und erhöht die Sicherheit des
Personals. In einer Zeit zunehmender
onsrisiken eliminiert das MD-Kova-
die Gefahr von Glasbnjch; Verschütten
: ontamination. Der MD-Kova-Objekt-
3 nun auch mit Zählräster, .ist leichter und
v! ' ' ·
Das Zählraster erleichtert
das Auffinden der
Sedimentebene. ·
Die Fläche eines Kleinst-
quadrates beträgt
0,33 mm 0,33 mm, das
Volumen des gesamten
Rasters 1 \.
schneller zu benutzen als dfe^herkömmlichen
Objektträger. Die optische Qualität entspricht
der von Glas,
Dabei können bis zu zehn Sedimentproben
ohne größeres Nachfokussiieren nacheinander
durchgemustert werden. Das Zählraster
verhindert, daß Gesichtsfelder doppelt gezählt
, werden, Eine Auswertetabelle liegt der Packung
bei.
Die höhe Präzision bringt die Sedimentanalyse
an die Genauigkeitsansprüche der klinischen
Chemie. .
Im EBM wurde eine eigene Abrechnüngs-
position für das MD-Kova^System geschaffen
(Ziffer 3622). ' .
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